Lead Optimization for Medicinal Chemists: Pharmacokinetic Properties of Functional Groups and Organic Compounds

Lead Optimization for Medicinal Chemists: Pharmacokinetic Properties of Functional Groups and Organic Compounds

Volumn , Issue , 2012, Pages

  Zaragoza Dörwald, Florencio ^a  

^a LONZA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84891570113     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527645640     Document Type: Book

References (116)

1. Newman, D.J. (2008) Natural products as leads to potential drugs: an old process or the new hope for drug discovery? J. Med. Chem., 51, 2589-2599.
2. Wermuth, C.G. (2004) Selective optimization of side activities: another way for drug discovery. J. Med. Chem., 47, 1303-1314.
3. Proudfoot, J.R. (2002) Drugs, leads, and drug-likeness: an analysis of some recently launched drugs. Bioorg. Med. Chem. Lett., 12, 1647-1650.
4. Rolan, P.E. (1994) Plasma protein binding displacement interactions - why are they still regarded as clinically important? Br. J. Clin. Pharmacol., 37, 125-128.
5. Hollósy, F., Valkó, K., Hersey, A., Nunhuck, S., Kéri, G., and Bevan, C. (2006) Estimation of volume of distribution in humans from high throughput HPLC-based measurements of human serum albumin binding and immobilized artificial membrane partitioning. J. Med. Chem., 49, 6958-6971
6. Lombardo, F., Obach, R.S., DiCapua, F.M., Bakken, G.A., Lu, J., Potter, D.M., Gao, F., Miller, M.D., and Zhang, Y. (2006) A hybrid mixture discriminant analysis-random forest computational model for the prediction of volume of distribution of drugs in human. J. Med. Chem., 49, 2262-2267
7. Gleeson, M.P., Water, N.J., Paine, S.W., and Davis, A.M. (2006) In silico human and rat Vss quantitative structure - activity relationship models. J. Med. Chem., 49, 1953-1963
8. Lombardo, F., Obach, R.S., Shalaeva, M.Y., and Gao, F. (2002) Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding dat. J. Med. Chem., 45, 2867-2876; (2004) J. Med. Chem., 47, 1242-1250.
9. Congreve, M., Chessari, G., Tisi, D., and Woodhead, A.J. (2008) Recent developments in fragment-based drug discovery. J. Med. Chem., 51, 3661-3680
10. Hajduk, P.J. (2006) Fragment-based drug design: how big is too big? J. Med. Chem., 49, 6972-6976
11. Boehm, H. et al. (2000) Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. J. Med. Chem., 43, 2664-2674
12. Maly, D.J., Choong, I.C., and Ellman, J.A. (2000) Combinatorial target-guided ligand assembly: identification of potent subtype-selective c-Src inhibitors. Proc. Natl. Acad. Sci. U.S.A., 97, 2419-2424
13. Hajduk, P.J., Meadows, R.P., and Fesik, S.W. (1997) Discovering high-affinity ligands for proteins. Science, 278, 497-499
14. Hann, M.M., Leach, A.R., and Harper, G. (2001) Molecular complexity and its impact on the probability of finding leads for drug discovery. J. Chem. Inf. Comput. Sci., 41, 856-864
15. Oprea, T.I., Davis, A.M., Teague, S.J., and Leeson, P.D. (2001) Is there a difference between leads and drugs? A historical perspective. J. Chem. Inf. Comput. Sci., 41, 1308-1315.
16. Zehnder, L. et al. (2011) Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of Heat Shock Protein 90. Identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2- difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide. J. Med. Chem., 54(9), 3368-3385
17. Eckhardt, M. et al. (2007) 8-(3-(R)-Aminopiperidin-1-yl)-7-but-3-ynyl- 3-methyl-1-(4-methylquinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. J. Med. Chem., 50, 6450-6453.
18. Warren, G.L. et al. (2006) A critical assessment of docking programs and scoring functions. J. Med. Chem., 49, 5912-5931.
19. Cozzini, P. et al. (2008) Target flexibility: an emerging consideration in drug discovery and design. J. Med. Chem., 51, 6237-6255.
20. Michel, J., Verdonk, M.L., and Essex, J.W. (2006) Protein-ligand binding affinity predictions by implicit solvent simulations: a tool for lead optimization? J. Med. Chem., 49, 7427-7439.
21. Selick, H.E., Beresford, A.P., and Tarbit, M.H. (2002) The emerging importance of predictive ADME simulation in drug discovery. Drug Discov. Today, 7, 109-116.
22. Wong, D.T., Perry, K.W., and Bymaster, F.P. (2005) The discovery of fluoxetine hydrochloride (prozac). Nat. Rev. Drug Discov., 4, 764-774.
23. Kubinyi, H. (2003) Drug research: myths, hype and reality. Nat. Rev. Drug Discov., 2, 665-668.
24. Lombardino, J.G. and Lowe, J.A. III (2004) The role of the medicinal chemist in drug discovery - then and now. Nat. Rev., 3, 853-862.
25. Ridley, M. (2010) The Rational Optimist. How Prosperity Evolves, Fourth Estate, London
26. Bastiat, F. (1996, first publishing date: 1845) The physiology of plunder, Economic Sophisms, Irvington-on-Hudson, The Foundation for Economic Education, Inc., New York http://www.econlib.org/library/Bastiat/basSoph5.html#S.2, Ch.1.
27. Lipinski, C.A., Lombardo, F., Dominy, B.W., and Feeney, P.J. (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev., 23, 3-25.
28. Gleeson, M.P. (2008) Generation of a set of simple, interpretable ADMET rules of thumb. J. Med. Chem., 51, 817-834.
29. Leeson, P.D. and Davis, A.M. (2004) Time-related differences in the physical property profiles of oral drugs. J. Med. Chem., 47, 6338-6348.
30. Lovering, F., Bikker, J., and Humblet, C. (2009) Escape from flatland: increasing saturation as an approach to improving clinical success. J. Med. Chem., 52, 6752-6756
31. Wassvik, C.M., Holmén, A.G., Draheim, R., Artursson, P., and Bergström, C.A.S. (2008) Molecular characteristics for solid-state limited solubility. J. Med. Chem., 51, 3035-3039.
32. O'Shea, R. and Moser, H.E. (2008) Physicochemical properties of antibacterial compounds: implications for drug discovery. J. Med. Chem., 51, 2871-2878.
33. Varma, M.V.S. et al. (2010) Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorbtion and first-pass elimination. J. Med. Chem., 53, 1098-1108
34. Linnankoski, J., Mäkelä, J.M., Ranta, V.-P., Urtti, A., and Yliperttula, M. (2006) Computational prediction of oral drug absorbtion based on absorbtion rate constants in humans. J. Med. Chem., 49, 3674-3681
35. Yoshida, F. and Topliss, J.G. (2000) QSAR model for drug human oral bioavailability. J. Med. Chem., 43, 2575-2785
36. Krämer, S.D. (1999) Absorbtion prediction from physicochemical parameters. Pharm. Sci. Technol. Today, 2, 373-380
37. Palm, K., Luthman, K., Ungell, A.-L., Strandlund, G., Beigi, F., Lundahl, P., and Artursson, P. (1998) Evaluation of dynamic polar molecular surface area as predictor of drug absorbtion: comparison with other computational and experimental predictors. J. Med. Chem., 41, 5382-5392
38. Winiwarter, S., Bonham, N.M., Ax, F., Hallberg, A., Lennernäs, H., and Karlén, A. (1998) Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. J. Med. Chem., 41, 4939-4949
39. von Geldern, T.W. et al. (1996) Azole endothelin antagonists .3. Using Δlog P as a tool to improve absorbtion. J. Med. Chem., 39, 982-991.
40. Veber, D.F., Johnson, S.R., Cheng, H., Smith, B.R., Ward, K.W., and Kopple, K.D. (2002) Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem., 45, 2615-2623
41. Wenlock, M.C., Austin, R.P., Barton, P., Davis, A.M., and Leeson, P.D. (2003) A comparison of physicochemical property profiles of development and marketed oral drugs. J. Med. Chem., 46, 1250-1256
42. See also (c) Lu, J.J. et al. (2004) Influence of molecular flexibility and polar surface area metrics on oral bioavailability in the rat. J. Med. Chem., 47, 6104-6107.
43. Broccatelli, F., Carosati, E., Neri, A., Frosini, M., Goracci, L., Oprea, T.I., and Cruciani, G. (2011) A novel approach for predicting p-glycoprotein (ABCB1) inhibition using molecular interaction fields. J. Med. Chem., 54, 1740-1751
44. Pajouhesh, H., and Lenz, G.R. (2005) Medicinal chemical properties of successful central nervous system drugs. J. Am. Soc. Exp. Neurotherapeutics, 2, 541-553
45. Pardridge, W.M. (1997) Drug delivery to the brain. J. Cereb. Blood Flow Metabol., 17, 713-731
46. Begley, D.J. (1996) The blood-brain barrier: principles for targeting peptides and drugs to the central nervous system. J. Pharm. Pharmacol., 48, 136-146.
47. Hitchcock, S.A. and Pennington, L.D. (2006) Structure-brain exposure relationships. J. Med. Chem., 49, 7559-7583
48. Kelder, J. et al. (1999) Polar molecular surface as a dominating determinant for oral absorbtion and brain penetration of drugs. Pharm. Res., 16, 1514-1519.
49. Rowley, M. et al. (1997) Effect of plasma protein binding on in vivo activity and brain penetration of glycine/NMDA receptor antagonists. J. Med. Chem., 40, 4053-4068.
50. Shaik, S., Cohen, S., Wang, Y., Chen, H., Kumar, D., and Thiel, W. (2010) P450 enzymes: their structure, reactivity, and selectivity-modeled by QM/MM calculations. Chem. Rev., 110, 949-1017
51. Yano, J.K., Denton, T.T., Cerny, M.A., Zhang, X., Johnson, E.F., and Cashman, J.R. (2006) Synthetic inhibitors of cytochrome P-450 2A6: inhibitory activity, difference spectra, mechanism of inhibition, and protein cocrystallization. J. Med. Chem., 49, 6987-7001
52. Burton, J., Ijjaali, I., Barberan, O., Petitet, F., Vercauteren, D.P., and Michel, A. (2006) Recursive partitioning for the prediction of cytochromes P450 2D6 and 1A2 inhibition: importance of the quality of the dataset. J. Med. Chem., 49, 6231-6240
53. Hudelson, M.G. and Jones, J.P. (2006) Line-walking method for predicting the inhibition of P450 drug metabolism. J. Med. Chem., 49, 4367-4373
54. de Groot, M., Ackland, M.J., Horne, V.A., Alex, A.A., and Jones, B.C. (1999) A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6. J. Med. Chem., 42, 4062-4070
55. Smith, D.A., Ackland, M.J., and Jones, B.C. (1997) Properties of cytochrome P450 isoenzymes and their substrates Part 1: active site characteristics, and Part 2: properties of cytochrome P450 substrates. Drug Discov. Today, 2, 406-414, 479-486.
56. Riley, R.J. (2001) The potential pharmacological and toxicological impact of P450 screening. Curr. Opin. Drug Discov. Dev., 4, 45-54.
57. Wilkinson, G.R. (2005) Drug metabolism and variability among patients in drug response. New Engl. J. Med., 352, 2211-2221
58. Lilja, J.J., Juntti-Patinen, L., and Neuvonen, P.J. (2004) Orange juice substantially reduces the bioavailability of the β-adrenergic blocking agent celiprolol. Clin. Pharmacol. Ther., 75, 184-190
59. Dresser, G.K., Bailey, D.G., Leake, B.F., Schwarz, U.I., Dawson, P.A., Freeman, D.J., and Kim, R.B. (2002) Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin. Pharmacol. Ther., 71, 11-20.
60. Ridley, J.M., Milnes, J.T., Hancox, J.C., and Witchel, H.J. (2006) Clemastine, a conventional antihistamine, is a high potency inhibitor of the hERG K+ channel. J. Mol. Cell. Cardiol., 40, 107-118.
61. Bischoff, U., Schmidt, C., Netzer, R., and Pongs, O. (2000) Effects of fluoroquinolones on hERG currents. Eur. J. Pharmacol., 406, 341-343.
62. Aronov, A.M. (2006) Common pharmacophores for uncharged human ether-a-go-go-related gene (hERG) blockers. J. Med. Chem, 49, 6917-6921
63. Jamieson, C., Moir, E.M., Rankovic, Z., and Wishart, G. (2006) Medicinal chemistry of hERG optimizations: highlights and hang-ups. J. Med. Chem., 49, 5029-5046
64. Cavalli, A., Poluzzi, E., De Ponti, F., and Recanatini, M. (2002) Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K+ channel blockers. J. Med. Chem., 45, 3844-3853.
65. Kalgutkar, A. (2010) Metabolic activation and idiosyncratic drug toxicity - by avoiding structural alerts, do we mitigate risks? Lecture given at the New England Drug Metabolism Discussion Group Summer Symposium 2010.
66. Kola, I. and Landis, J. (2004) Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov., 3, 711-716
67. Roberts, S.A. (2003) Drug metabolism and pharmacokinetics in drug discovery. Curr. Opin. Drug Discov. Dev., 6, 66-80.
68. Obach, R.S., Kalgutkar, A.S., Ryder, T.F., and Walker, G.S. (2008) In vitro metabolism and covalent binding of enol-carboxamide derivatives and anti-inflammatory agents sudoxicam and meloxicam: insights into the hepatotoxicity of sudoxicam. Chem. Res. Toxicol., 21, 1890-1899.
69. Uetrecht, J., Zahid, N., Tehim, A., Fu, J.M., and Rakhit, S. (1997) Structural features associated with reactive metabolite formation in clozapine analogues. Chem. Biol. Interact., 104, 117-129
70. Liu, Z.C. and Uetrecht, J.P. (1995) Clozapine is oxidized by activated human neutrophils to a reactive nitrenium ion that irreversibly binds to the cells. J. Pharmacol. Exp. Ther., 275, 1476-1483.
71. Leone, A.M., Kao, L.M., McMillan, M.K., Nie, A.Y., Parker, J.B., Kelley, M.F., Usuki, E., Parkinson, A., Lord, P.G., and Johnson, M.D. (2007) Evaluation of felbamate and other antiepileptic drug toxicity potential based on hepatic protein covalent binding and gene expression. Chem. Res. Toxicol., 20, 600-608
72. Dieckhaus, C.M., Thompson, C.D., Roller, S.G., and Macdonald, T.L. (2002) Mechanisms of idiosyncratic drug reactions: the case of felbamate. Chem. Biol. Interact., 142, 99-117
73. Thompson, C.D. et al. (1999) Quantification of patient urine samples of felbamate and three metabolites: acid carbamate and two mercapturic acids. Epilepsia, 40, 769-776.
74. Bauman, J.N., Kelly, J.M., Tripathy, S., Zhao, S.X., Lam, W.W., Kalgutkar, A.S., and Obach, R.S. (2009) Can in vitro metabolism-dependent covalent binding data distinguish hepatotoxic from nonhepatotoxic drugs? An analysis using human hepatocytes and liver S-9 fraction. Chem. Res. Toxicol., 22, 332-340
75. Obach, R.S., Kalgutkar, A.S., Soglia, J.R., and Zhao, S.X. (2008) Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose. Chem. Res. Toxicol., 21, 1814-1822.
76. Schwöbel, J.A.H., Koleva, Y.K., Enoch, S.J., Bajot, F., Hewitt, M., Madden, J.C., Roberts, D.W., Schultz, T.W., and Cronin, M.T.D. (2011) Measurement and estimation of electrophilic reactivity for predictive toxicology. Chem. Rev., 111, 2562-2596
77. Benigni, R. and Bossa, C. (2011) Mechanisms of chemical carcinogenicity and mutagenicity: a review with implications for predictive toxicology. Chem. Rev., 111, 2507-2536
78. Benigni, R. (2005) Structure-activity relationship studies of chemical mutagens and carcinogens: mechanistic investigations and prediction approaches. Chem. Rev., 105, 1767-1800.
79. Ishikawa, M. and Hashimoto, Y. (2011) Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry. J. Med. Chem., 54, 1539-1554
80. Ginnings, P.M. and Baum, R. (1937) Aqueous solubilities of the isomeric pentanols. J. Am. Chem. Soc., 59, 1111-1113
81. Stephenson, R. and Stuart, J. (1986) Mutual binary solubilities: water-alcohols and water-esters. J. Chem. Ing., 31, 56-70.
82. Köppel, C. and Tenczer, J. (1984) A revision of the metabolic disposition of amantadine. Biol. Mass Spectrom., 12, 499-501.
83. Weaver, M.L. et al. (2001) Pharmacokinetics and metabolism of nateglinide in humans. Drug Metab. Dispos., 29, 415-421.
84. Ballinger, P. and Long, F.A. (1960) Acid ionization constants of alcohols. II. Acidities of some substituted methanols and related compounds. J. Am. Chem. Soc., 82, 795-798
85. Hine, J., Yeh, C.Y., and Schmalstieg, F.C. (1970) Polar effects on the formation of imines from isobutyraldehyde and primary aliphatic amines. J. Org. Chem., 35, 340-344.
86. Pulver, R. and Litvan, F. (1960) Über den Stoffwechsel des 2-Methoxy- 4-allylphenoxyessigsäure-N, N-diäthylamid. Arzneimittel-Forsch., 10, 111-113.
87. Dow, J., Piriou, F., Wolf, E., Dulery, B.D., and Haegele, K.D. (1994) Novel carbamate metabolites of mofegiline, a primary amine monoamine oxidase B inhibitor, in dogs and humans. Drug Metab. Dispos., 22, 738-749.
88. Hagmann, W.K. (2008) The many roles for fluorine in medicinal chemistry. J. Med. Chem., 51, 4359-4369
89. Park, B.K., Kitteringham, N.R., and O'Neill, P.M. (2001) Metabolism of fluorine-containing drugs. Annu. Rev. Pharmacol. Toxicol., 41, 443-470
90. Patani, G.A. and LaVoie, E.J. (1996) Bioisosterism: a rational approach in drug design. Chem. Rev., 96, 3147-3176
91. Park, B.K. and Kitteringham, N.R. (1994) Effects of fluorine substitution on drug metabolism: pharmacological and toxicological implication. Drug Metabol. Rev., 26, 605-64
92. Sneader, W. (1999) Organic nitrates. Drug News Perspect., 12, 58-63.
93. Durant, G.J., Emmett, J.C., Ganellin, C.R., Miles, P.D., Parsons, M.E., Prain, H.D., and White, G.R. (1977) Cyanoguanidine-thiourea equivalence in the development of the histamine H2-receptor antagonist, cimetidine. J. Med. Chem., 20, 901-906.
94. Sneader, W. (1996) Curare. Drug News Perspect., 9, 627-630;
95. Sneader, W. (1997) Synthetic muscle relaxants. Drug News Perspect., 10, 113-117.
96. Reeh, C., Wundt, J., and Clement, B. (2007) N, Ń-Dihydroxyamidines: a new prodrug principle to improve the oral bioavailability of amidines. J. Med. Chem., 50, 6730-6734.
97. Buchwald, P. and Bodor, N. (1999) Quantitative structure-metabolism relationships: steric and nonsteric effects in the enzymatic hydrolysis of noncongener carboxylic esters. J. Med. Chem., 42, 5160-5168.
98. Fleming, F.F., Yao, L., Ravikumar, P.C., Funk, L., and Shook, B.C. (2010) Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore. J. Med. Chem., 53, 7902-7917.
99. Silver, E.H., Kuttab, S.H., Hasan, T., and Hassan, M. (1982) Structural considerations in the metabolism of nitriles to cyanide in vivo. Drug Metabol. Dispos., 10, 495-498;
100. Dahl, A.R. and Waruszewski, B.A. (1989) Metabolism of organonitriles to cyanide by rat nasal tissue enzymes. Xenobiotica, 19, 1201-1205.
101. Trescot, A.M., Datta, S., Lee, M., and Hansen, H. (2008) Opioid pharmacology. Pain Physician, 11, S133-S153;
102. Sneader, W. (1998) The discovery of heroin. Lancet, 352, 1697-1699.
103. Bromidge, S.M. et al. (2000) Biarylcarbamoylindolines are novel and selective 5-HT2C receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent. J. Med. Chem., 43, 1123-1134.
104. Carlsson, E., Lindberg, P., and von Unge, S. (May 2002) Two of a kind. Chem. Br., 42-45.
105. De Clercq, E. (2010) Highlights in the discovery of antiviral drugs: a personal retrospective. J. Med. Chem., 53, 1438-1450;
106. Parker, W.B. (2009) Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer. Chem. Rev., 109, 2880-2893.
107. Sneader, W. (1997) Diuretics. Drug News Perspect., 10, 364-369.
108. Sternbach, L.H. (1979) The benzodiazepine story. J. Med. Chem., 22, 1-7.
109. Oelschlaeger, P., Ai, N., DuPrez, K.T., Welsh, W.J., and Toney, J.H. (2010) Evolving carbapenemases: can medicinal chemists advance one step ahead of the coming storm? 524 70 β-Lactams J. Med. Chem., 53, 3013-3027;
110. Taubes, G. (2008) The bacteria fight back. Science, 321, 356-361;
111. Walsh, C. and Wright, G. (2005) Antibiotic resistance. Chem. Rev., 105, 391-393;
112. Fisher, J.F., Meroueh, S.O., and Mobashery, S. (2005) Bacterial resistance to β-lactam antibiotics: compelling opportunism, compelling opportunity. Chem. Rev., 105, 395-424.
113. Bhardwaj, G. (2006) How the anti-hypertensive losartan was discovered. Expert Opin. Drug Discov., 1, 609-618;
114. Timmermans, P.B., Wong, P.C., Chiu, A.T., Herblin, W.F., Benfield, P., Carini, D.J., Lee, R.J., Wexler, R.R., Saye, J.A.M., and Smith, R.D. (1993) Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol. Rev., 45, 205-251.
115. Skwarczynski, M., Hayashi, Y., and Kiso, Y. (2006) Paclitaxel prodrugs: toward smarter delivery of anticancer agents. J. Med. Chem., 49, 7253-7269.
116. Marsault, E. and Peterson, M.L. (2011) Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery. J. Med. Chem., 54, 1961-2004.